Vinorelbine (Navelbine®) in the treatment of non-small-cell lung cancer: Studies with single-agent therapy and in combination with cisplatin

Richard J. Gralla, P. Harper, S. Johnson, F. M. Delgado

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Initial studies of vinorelbine (Navelbine®) given as a single agent to patients with operable non-small-cell lung cancer (NSCLC) showed that overall response rates of the order of 30% could be obtained with a schedule of 30 mg/m2 given weekly. Although such high levels of response have seldom been obtained when vinorelbine is given alone in one arm of a comparative study, the level of activity is clearly worthwhile and represents a significant improvement over supportive care. Combination therapy with cisplatin has been highly successful, establishing Vinorelbine as a safe well-tolerated agent which provides considerable activity, and experience from large phase III studies suggests that the combination of vinorelbine and cisplatin could represent a reference schedule against which other therapy should be compared.

Original languageEnglish (US)
JournalAnnals of Oncology
Volume10
Issue numberSUPPL. 5
StatePublished - 1999
Externally publishedYes

Fingerprint

Non-Small Cell Lung Carcinoma
Cisplatin
Appointments and Schedules
Therapeutics
Proxy
vinorelbine

Keywords

  • Cisplatin
  • Non-small-cell lung cancer
  • Vinorelbine

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Vinorelbine (Navelbine®) in the treatment of non-small-cell lung cancer : Studies with single-agent therapy and in combination with cisplatin. / Gralla, Richard J.; Harper, P.; Johnson, S.; Delgado, F. M.

In: Annals of Oncology, Vol. 10, No. SUPPL. 5, 1999.

Research output: Contribution to journalArticle

@article{a5040b74d467472a82ade53863d070a2,
title = "Vinorelbine (Navelbine{\circledR}) in the treatment of non-small-cell lung cancer: Studies with single-agent therapy and in combination with cisplatin",
abstract = "Initial studies of vinorelbine (Navelbine{\circledR}) given as a single agent to patients with operable non-small-cell lung cancer (NSCLC) showed that overall response rates of the order of 30{\%} could be obtained with a schedule of 30 mg/m2 given weekly. Although such high levels of response have seldom been obtained when vinorelbine is given alone in one arm of a comparative study, the level of activity is clearly worthwhile and represents a significant improvement over supportive care. Combination therapy with cisplatin has been highly successful, establishing Vinorelbine as a safe well-tolerated agent which provides considerable activity, and experience from large phase III studies suggests that the combination of vinorelbine and cisplatin could represent a reference schedule against which other therapy should be compared.",
keywords = "Cisplatin, Non-small-cell lung cancer, Vinorelbine",
author = "Gralla, {Richard J.} and P. Harper and S. Johnson and Delgado, {F. M.}",
year = "1999",
language = "English (US)",
volume = "10",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "Oxford University Press",
number = "SUPPL. 5",

}

TY - JOUR

T1 - Vinorelbine (Navelbine®) in the treatment of non-small-cell lung cancer

T2 - Studies with single-agent therapy and in combination with cisplatin

AU - Gralla, Richard J.

AU - Harper, P.

AU - Johnson, S.

AU - Delgado, F. M.

PY - 1999

Y1 - 1999

N2 - Initial studies of vinorelbine (Navelbine®) given as a single agent to patients with operable non-small-cell lung cancer (NSCLC) showed that overall response rates of the order of 30% could be obtained with a schedule of 30 mg/m2 given weekly. Although such high levels of response have seldom been obtained when vinorelbine is given alone in one arm of a comparative study, the level of activity is clearly worthwhile and represents a significant improvement over supportive care. Combination therapy with cisplatin has been highly successful, establishing Vinorelbine as a safe well-tolerated agent which provides considerable activity, and experience from large phase III studies suggests that the combination of vinorelbine and cisplatin could represent a reference schedule against which other therapy should be compared.

AB - Initial studies of vinorelbine (Navelbine®) given as a single agent to patients with operable non-small-cell lung cancer (NSCLC) showed that overall response rates of the order of 30% could be obtained with a schedule of 30 mg/m2 given weekly. Although such high levels of response have seldom been obtained when vinorelbine is given alone in one arm of a comparative study, the level of activity is clearly worthwhile and represents a significant improvement over supportive care. Combination therapy with cisplatin has been highly successful, establishing Vinorelbine as a safe well-tolerated agent which provides considerable activity, and experience from large phase III studies suggests that the combination of vinorelbine and cisplatin could represent a reference schedule against which other therapy should be compared.

KW - Cisplatin

KW - Non-small-cell lung cancer

KW - Vinorelbine

UR - http://www.scopus.com/inward/record.url?scp=0032692677&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032692677&partnerID=8YFLogxK

M3 - Article

C2 - 10582138

AN - SCOPUS:0032692677

VL - 10

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - SUPPL. 5

ER -